Effects of combined ciprofloxacin and Neulasta therapy on intestinal pathology and gut microbiota after high-dose irradiation in mice

• DOI: 10.3389/fpubh.2024.1365161
• Publication Date: 2024-05-14T04:54:52Z
• Authors: Timothy S. Horseman; Andrew M. Frank; Georgetta Cannon; Min Zhai; Matthew G. Olson; Bin Lin; Xianghong Li; Lisa Hull; Mang Xiao; Juliann G. Kiang; David M. Burmeister
• Keywords: Male; 0301 basic medicine; gut microbiota; gastrointestinal; acute radiation syndrome; Gastrointestinal Microbiome; Anti-Bacterial Agents; Mice; 03 medical and health sciences; Acute Radiation Syndrome; ciprofloxacin; Ciprofloxacin; Gamma Rays; Animals; Female; Public Health; Public aspects of medicine; RA1-1270; Neulasta

Treatments that currently exist in the strategic national stockpile for acute radiation syndrome (ARS) focus on hematopoietic subsyndrome, with no treatments gastrointestinal (GI)-ARS. While gut microbiota helps maintain host homeostasis by mediating GI epithelial and mucosal integrity, exposure can alter commensal which may leave susceptible to opportunistic pathogens serious sequelae such as sepsis. To mitigate effects of ARS irradiation, approved form colony stimulating factors antibiotics: however, there are few studies examining how these therapeutics affect GI-ARS microbiota. The aim our study was examine longitudinal Neulasta and/or ciprofloxacin treatment after 9.5 Gy